Monsanto Licenses CRISPR/Cpf1 From Broad Institute | GenomeWeb

NEW YORK (GenomeWeb) – Agricultural giant Monsanto has licensed CRISPR/Cpf1 genome editing technology from the Broad Institute.

Under the terms of the agreement, Monsanto gains worldwide, non-exclusive rights to agricultural applications of the CRISPR/Cpf1 system.

Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.